Inova Health Taps Anomaly Insights AI to Recover $10.4 Million in 90 Days on Payer Claims

Inova Health System identified $10.4 million in recovered revenue opportunities within the first 90 days of a new partnership with Anomaly Insights, an AI-powered payer intelligence startup. The health system estimates the collaboration now generates $3.8 million in ongoing monthly revenue impact, according to a September 10 press release announcing the deal.

The thesis behind the partnership is straightforward. Health systems lose meaningful revenue to payer denials, downcoding, and administrative friction that is hard to track at scale without better data tools. Anomaly's technology is designed to give providers visibility into that friction, and Inova's early numbers offer a concrete data point on what that visibility might be worth.

"Every dollar we recover through this work is a dollar we can reinvest in the patients and communities we serve," said Erin Hodson, Inova's vice president of revenue cycle, in a statement. "By bringing greater visibility and transparency to complex payment processes, we can make more informed decisions and continue strengthening our approach to revenue management."

How the technology works

Anomaly's core offering, called Manage, examines claims data across every payer in a health system's contract portfolio. The tool synthesizes information from contracts through to individual claims, identifying patterns that would be difficult for revenue cycle staff to spot manually across thousands of transactions. Specifically, it flags instances where a payer denies a claim that should have been paid, or downcodes a service to a lower-reimbursement billing code.

That granularity matters. Denials and downcoding are common friction points in the provider-payer relationship, but they are often scattered across so many claims and payer contracts that systematic patterns go unnoticed. An AI system that can process claims volume at scale and cross-reference it against contract terms is, in theory, well suited to catching what human review misses.

Anomaly launched the Manage tool in June, positioning it as a resource for managed care executives heading into payer negotiations. The idea is to arm those executives with evidence, rather than anecdote, when they sit across the table from insurers. The Inova partnership extends that concept into day-to-day revenue cycle operations, where Anomaly is now providing additional data and analytics to evaluate payer behavior and payment outcomes on an ongoing basis.

Anomaly CEO Mike Desjadon described the engagement with Inova in personal terms. "The Inova team is already world-class, but the totality of what they're up against with insurance companies is genuinely hard to believe until you see the data," he told Fierce Healthcare. He added that seeing how directly Inova ties recovered revenue back to patient care "really connected our team to that same sense of purpose."

Desjadon also framed the work in mission-driven language, saying Anomaly is "proud to support Inova's mission" and that the company finds it "deeply rewarding" to help prevent what he called improper denials from reaching families.

Executives at Inova say the Anomaly partnership fits into a broader strategy of embedding AI directly into revenue cycle and managed care functions, rather than treating it as a bolt-on tool for isolated tasks. That framing aligns with a trend showing up across the health system landscape. Over the past year, hospital executives have repeatedly flagged, in earnings calls, industry surveys, and other forums, a growing interest in tech-based approaches to maximize reimbursement even as systems navigate tight margins and rising operating costs.

Why it matters

Revenue cycle management has become one of the more crowded and closely watched corners of healthcare AI. Health systems operate on thin margins, and the gap between what payers owe and what they actually pay, whether through denials, downcoding, or delayed adjudication, represents a persistent drag on operating performance. Tools that can quantify and close that gap carry an obvious appeal for finance and revenue cycle leadership.

The Inova figures are notable because they are specific and time-bound. A $10.4 million identification in 90 days, with $3.8 million in projected ongoing monthly impact, gives other health systems a benchmark to evaluate against their own claims volume and payer mix. It also gives Anomaly a case study to point to as it competes for additional health system clients in a market where several vendors now offer AI-driven denial management and payer analytics.

That said, these are early-stage results from a single partnership, self-reported by the two parties involved. There is no independent audit referenced in the announcement, and the figures represent identified opportunity and estimated impact rather than fully realized, collected cash. The distinction between money identified and money actually collected matters in revenue cycle work, where recovery rates on flagged claims can vary significantly depending on payer responsiveness and appeals success.

The broader industry context adds some weight to the claims, however. Executive commentary over the past year has consistently pointed toward AI adoption in revenue cycle as a priority area, suggesting Inova's move is representative of a sector-wide shift rather than an outlier bet.

Key Figures

The numbers anchoring this partnership are worth restating plainly. Inova identified $10.4 million in recovered revenue opportunities in the first 90 days of working with Anomaly. The health system projects $3.8 million in ongoing monthly revenue impact going forward. Anomaly's Manage tool, launched in June, underpins the analytical work, scanning claims across all payers in a system's contract set to surface denial and downcoding patterns.

For health system finance leaders evaluating similar tools, the key question is not whether AI can flag payer discrepancies, evidence increasingly suggests it can, but how quickly identified opportunities convert into collected revenue, and at what implementation cost. Inova's disclosed figures offer a starting benchmark, but the durability of that $3.8 million monthly estimate over a longer horizon will be the real test of the partnership's value.